SC75741
Based on 32 publication(s) in Google Scholar
SC75741 is a broad and efficient NF-κB inhibitor with an IC50 of 200 nM for p65. SC75741 blocks influenza viruses (IV) replication. SC75741 impairs DNA binding of the NF-κB subunit p65, resulting in reduced expression of cytokines, chemokines, and pro-apoptotic factors. SC75741 subsequently inhibits caspase activation and blocks caspase-mediated nuclear export of viral ribonucleoproteins.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.24%
- No. CAS: 913822-46-5
- Fòrmula: C29H23N7O2S2
- Peso molecular:565.67
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) SC75741
More- Sci Bull. 2025 May 30;70(10):1673-1690. [Abstract]
- J Clin Invest. 2026 Mar 17:e199056. [Abstract]
- J Clin Invest. 2024 Oct 1;134(22):e178628. [Abstract]
- Cell Rep Med. 2024 May 29:101592. [Abstract]
- Cell Mol Biol Lett. 2025 May 7;30(1):57. [Abstract]
- Diabetologia. 2025 Jun;68(6):1335-1351. [Abstract]
- Cell Commun Signal. 2025 Oct 28;23(1):464. [Abstract]
- Phytomedicine. 2024 Apr:126:155450. [Abstract]
- Free Radic Biol Med. 2024 Jun 1:S0891-5849(24)00506-9. [Abstract]
- Cell Rep. 2025 Sep 24;44(10):116342. [Abstract]
- Oncogenesis. 2023 Mar 29;12(1):18. [Abstract]
- EMBO Rep. 2020 Nov 5;21(11):e49305. [Abstract]
- Int J Mol Med. 2025 May;55(5):78. [Abstract]
- Inflammation. 2024 Dec 10. [Abstract]
- CNS Neurosci Ther. 2021 May;27(5):552-563. [Abstract]
- PLoS Pathog. 2024 Mar 1;20(3):e1012031. [Abstract]
- Int Immunopharmacol. 2026 May 1:176:116462. [Abstract]
- Am J Physiol Cell Physiol. 2025 Apr 16. [Abstract]
- Int Immunopharmacol. 2025 Jan 27:148:114180. [Abstract]
- Int Immunopharmacol. 2024 Dec 25:146:113938. [Abstract]
- Eur J Pharmacol. 2020 Oct 15;885:173399. [Abstract]
- Mol Neurobiol. 2024 Dec;61(12):10246-10270. [Abstract]
- J Cell Mol Med. 2021 Jun;25(12):5457-5469. [Abstract]
- Poultry Sci. 2021 May;100(5):101085. [Abstract]
- J Cell Mol Med. 2021 May;25(10):4709-4720. [Abstract]
- Sci Rep. 2026 Mar 12;16(1):13227. [Abstract]
- Mol Biol Rep. 2026 Mar 27;53(1):551. [Abstract]
- J Biochem Mol Toxicol. 2025 Sep;39(9):e70479. [Abstract]
- Immunol Invest. 2025 May 14:1-27. [Abstract]
- McGill University. 2026.
- Zoonoses. 2023 Feb 11.
- Research Square Preprint. 2021 Dec.
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
RT-PCR
-
WB
-
Cell Proliferation/Viability Assay
Actividad biológica
|
p65 200 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
0.2 μM
Compound: 13
|
Inhibition of NF-kappaB in A549 cells after 5 hrs by reporter gene assay
Inhibition of NF-kappaB in A549 cells after 5 hrs by reporter gene assay
|
[PMID: 17869512] |
| PBMC | IC50 |
2.2 μM
Compound: 13
|
Antiproliferative activity against human PBMC
Antiproliferative activity against human PBMC
|
[PMID: 17869512] |
| THP1-Dual | IC50 |
3958 nM
Compound: SC75741
|
Inhibition of LPS induced ISG activation in human THP1-Dual cells pretreated with LPS-B5 for 3 hrs followed by compound addition incubated for 24 hrs
Inhibition of LPS induced ISG activation in human THP1-Dual cells pretreated with LPS-B5 for 3 hrs followed by compound addition incubated for 24 hrs
|
[PMID: 36053746] |
| THP1-Dual | IC50 |
5975 nM
Compound: SC75741
|
Inhibition of LPS induced NF kappa B activation in human THP1-Dual cells stimulated with LPS-B5 for 3 hrs followed by compound addition incubated for 24 hrs
Inhibition of LPS induced NF kappa B activation in human THP1-Dual cells stimulated with LPS-B5 for 3 hrs followed by compound addition incubated for 24 hrs
|
[PMID: 36053746] |
SC75741 (5 μM; 24-96 hours) inhibits long-term A549 cells proliferation[2].
SC75741 (1-10 μM; 5.5-65 hours) reduces A549 cells viability in a concentration-dependent manner indicating a cytostatic effect for A549 cells within a time frame of about 50 and 65 hours[2].
SC75741 (5 μM; 24 hours) strongly inhibits cleavage of the effector caspase 3 induced upon H7N7-infection[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:5 μM
-
Incubation Time:24, 48, 72 and 96 hours
-
Result:Inhibited long-term cell proliferation
-
Cell Line:A549 cells
-
Concentration:1, 2, 5 or 10 μM
-
Incubation Time:5.5, 29, 50, 65 hours
-
Result:Reduced cells viability in a concentration-dependent manner.
-
Cell Line:MDCK cells
-
Concentration:5 μM
-
Incubation Time:24 hours
-
Result:Inhibited cleavage of the effector caspase 3 induced upon H7N7-infection.
The plasma-levels of SC74751 (intravenously of 5 mg/kg and intraperitoneally of 15 mg/kg; for 3.5 and 6 hours) after i.v. administration decreases mono-exponentially and half-life is roughly 40 min. After i.p. administration, elimination of SC75741 seems to be limited by a slow uptake from the peritoneum and a half-life of 55 min is observed[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Inbred female C57BL/6 mice at the age of 6-8 weeks[2]
-
Dosage:15 mg/kg
-
Administration:Intraperitoneal injection; for 2 days
-
Result:Reduced the amount of viral mRNA by 90%.
-
Animal Model:Inbred female C57BL/6 mice at the age of 6-8 weeks[1]
-
Dosage:5 mg/kg or 15 mg/kg
-
Administration:Intravenously of 5 mg/kg and intraperitoneally of 15 mg/kg; 3.5 and 6 hours
-
Result:Half-life was roughly 40 min and 55 min for i.v. and i.p. administration, respectively.
Chemical Information
-
No. CAS 913822-46-5
-
Appearance Solid
-
Peso molecular 565.67
-
Fòrmula C29H23N7O2S2
-
Color Light yellow to brown
-
SMILES
O=C(NC1=NC(C=CC(C(C2=CC=CC=C2)=O)=C3)=C3N1)C4=CSC(C(CC5)CCN5C6=NC=NC7=C6SC=C7)=N4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Sci Bull
Initial cardioplegic flush with crystalloid cardioplegia improves donor heart preservation and function via NR4A3 upregulation and metabolic reprogramming. [Abstract]2025 May 30;70(10):1673-1690. PMID: 40190001
SC75741 purchased from MedChemExpress. Usage Cited in: Sci Bull. 2025 May 30;70(10):1673-1690. [Abstract]
SC75741 (5 μmol/L). Western blot analysis showed that SC75741 treatment significantly downregulated the expression of p-p65 (Ser529).
SC75741 purchased from MedChemExpress. Usage Cited in: Sci Bull. 2025 May 30;70(10):1673-1690. [Abstract]
SC75741 (5 μmol/L). The fluorescence staining confirmed NFκB inhibition led to less myocardial apoptosis and ROS production after 8-hours SCS.
-
J Clin Invest
Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models. [Abstract]2026 Mar 17:e199056. PMID: 41842961 -
J Clin Invest
Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. [Abstract]2024 Oct 1;134(22):e178628. PMID: 39352749
SC75741 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(22):e178628. [Abstract]
Relative mRNA expression of OLFML3 in PTEN-KO SF763 cells expressing shC and shLOX treated with or without P65 inhibitor (P65i) SC75741 (5 μM, 24h).
SC75741 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(22):e178628. [Abstract]
Immunoblots for OLFML3 in lysates of PTEN-WT SF763 cells expressing shC and shPATZ1 treated with or without P65i SC75741 (5 μM, 24h).
-
Cell Rep Med
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]2024 May 29:101592. PMID: 38843841
SC75741 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 29:101592. [Abstract]
MV4-11 cells stimulated in LDM supplied with different reagents (PA, 20 μM; OxLDL, 25 μg/mL; SC75741, 5 μM) for 3 days were further used for T cell proliferation assay (n = 3).
SC75741 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 29:101592. [Abstract]
Different kinds of MV4-11 cells were used for T cell proliferation assay (n = 3). SC75741 (5 μM) was added.
-
Cell Mol Biol Lett
Immunodynamic axis of fibroblast-driven neutrophil infiltration in acute pancreatitis: NF-κB-HIF-1α-CXCL1. [Abstract]2025 May 7;30(1):57. PMID: 40335899 -
Diabetologia
MAP4K4 aggravates microvascular anomalies in diabetic retinopathy in a YTHDF2-dependent manner. [Abstract]2025 Jun;68(6):1335-1351. PMID: 40072537 -
Cell Commun Signal
Senescent cells promote viral infection-associated inflammation and tissue damage through a robust NF-κB pathway. [Abstract]2025 Oct 28;23(1):464. PMID: 41152908 -
Phytomedicine
Shen-Shuai-II-Recipe inhibits tubular inflammation by PPARα-mediated fatty acid oxidation to attenuate fibroblast activation in fibrotic kidneys. [Abstract]2024 Apr:126:155450. PMID: 38368794 -
Free Radic Biol Med
Cannabidiol mitigates radiation-induced intestine ferroptosis via facilitating the heterodimerization of RUNX3 with CBFβ thereby promoting transactivation of GPX4. [Abstract]2024 Jun 1:S0891-5849(24)00506-9. PMID: 38830513 -
Cell Rep
2025 Sep 24;44(10):116342. PMID: 41004340 -
Oncogenesis
Transgelin promotes lung cancer progression via activation of cancer-associated fibroblasts with enhanced IL-6 release. [Abstract]2023 Mar 29;12(1):18. PMID: 36990991 -
EMBO Rep
PEBP1 suppresses HIV transcription and induces latency by inactivating MAPK/NF-κB signaling. [Abstract]2020 Nov 5;21(11):e49305. PMID: 32924251 -
Int J Mol Med
Platelet activation stimulates macrophages to enhance ulcerative colitis through PF4/CXCR3 signaling. [Abstract]2025 May;55(5):78. PMID: 40084691 -
Inflammation
REGγ-mediated Barrier Disruption and NF-κB Activation Aggravates Intestinal Inflammation in Necrotizing Enterocolitis. [Abstract]2024 Dec 10. PMID: 39653983 -
CNS Neurosci Ther
2021 May;27(5):552-563. PMID: 33460245 -
PLoS Pathog
Candida albicans translocation through the intestinal epithelial barrier is promoted by fungal zinc acquisition and limited by NFκB-mediated barrier protection. [Abstract]2024 Mar 1;20(3):e1012031. PMID: 38427950 -
Int Immunopharmacol
2026 May 1:176:116462. PMID: 41797086 -
Am J Physiol Cell Physiol
Immunoproteasome subunit PSMB8 promotes skeletal muscle regeneration by regulating macrophage phenotyping switch in mice. [Abstract]2025 Apr 16. PMID: 40241316 -
Int Immunopharmacol
Long non-coding RNA NRIR inhibits osteogenesis in peri-implantitis by promoting NLRP3 inflammasome-mediated macrophage pyroptosis. [Abstract]2025 Jan 27:148:114180. PMID: 39874847 -
Int Immunopharmacol
2024 Dec 25:146:113938. PMID: 39724736 -
Eur J Pharmacol
Daidzein ameliorates LPS-induced hepatocyte injury by inhibiting inflammation and oxidative stress. [Abstract]2020 Oct 15;885:173399. PMID: 32712091 -
Mol Neurobiol
Transcriptome Analysis Reveals Dynamic Microglial-Induced A1 Astrocyte Reactivity via C3/C3aR/NF-κB Signaling After Ischemic Stroke. [Abstract]2024 Dec;61(12):10246-10270. PMID: 38713438 -
J Cell Mol Med
HIF-1α is necessary for activation and tumour-promotion effect of cancer-associated fibroblasts in lung cancer. [Abstract]2021 Jun;25(12):5457-5469. PMID: 33943003 -
Poultry Sci
SC75741 antagonizes vesicular stomatitis virus, duck Tembusu virus, and duck plague virus infection in duck cells through promoting innate immune responses. [Abstract]2021 May;100(5):101085. PMID: 33799115 -
J Cell Mol Med
S100A9 induces nucleus pulposus cell degeneration through activation of the NF-κB signaling pathway. [Abstract]2021 May;25(10):4709-4720. PMID: 33734570 -
Sci Rep
Targeted deletion of c-kit in TECs attenuates UUO-induced renal fibrosis through NF-κB pathway inhibition. [Abstract]2026 Mar 12;16(1):13227. PMID: 41820550 -
Mol Biol Rep
Porphyromonas gingivalis-derived lipopolysaccharide confers chemotherapy resistance and migratory ability on oral cancer cells by activating toll-like receptor 4 signaling pathway. [Abstract]2026 Mar 27;53(1):551. PMID: 41894086 -
J Biochem Mol Toxicol
Brucine Inhibits Gastric Cancer via Activation of Ferroptosis Through Regulating the NF-κB Signaling Pathway. [Abstract]2025 Sep;39(9):e70479. PMID: 40919637 -
Immunol Invest
Mechanistic Insights into HOTAIR-Driven ADAM17/NF-Κb Activation and Endothelial Dysfunction in LPS-Challenged HUVECs. [Abstract]2025 May 14:1-27. PMID: 40366882 -
-
-
Solvente y solubilidad
DMSO : 83.33 mg/mL (147.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.68 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Haasbach E, et al. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral Res. 2013 Sep;99(3):336-44. [Content Brief]
[2]. Ehrhardt C, et al. The NF-κB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance. Cell Microbiol. 2013 Jul;15(7):1198-211. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7678 mL | 8.8391 mL | 17.6782 mL | 44.1954 mL |
| 5 mM | 0.3536 mL | 1.7678 mL | 3.5356 mL | 8.8391 mL | |
| 10 mM | 0.1768 mL | 0.8839 mL | 1.7678 mL | 4.4195 mL | |
| 15 mM | 0.1179 mL | 0.5893 mL | 1.1785 mL | 2.9464 mL | |
| 20 mM | 0.0884 mL | 0.4420 mL | 0.8839 mL | 2.2098 mL | |
| 25 mM | 0.0707 mL | 0.3536 mL | 0.7071 mL | 1.7678 mL | |
| 30 mM | 0.0589 mL | 0.2946 mL | 0.5893 mL | 1.4732 mL | |
| 40 mM | 0.0442 mL | 0.2210 mL | 0.4420 mL | 1.1049 mL | |
| 50 mM | 0.0354 mL | 0.1768 mL | 0.3536 mL | 0.8839 mL | |
| 60 mM | 0.0295 mL | 0.1473 mL | 0.2946 mL | 0.7366 mL | |
| 80 mM | 0.0221 mL | 0.1105 mL | 0.2210 mL | 0.5524 mL | |
| 100 mM | 0.0177 mL | 0.0884 mL | 0.1768 mL | 0.4420 mL |
Powered by Bioz